Rutgers Cancer Institute of New Jersey prevails, as the State of New Jersey's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, to satisfy the cancer research demands of one of the most diverse and densely populated states in the nation. As a matrix and consortium cancer center that has been continuously funded by the NCI Cancer Center Support Grant (CCSG P30CA072720) mechanism since 1997, Rutgers Cancer Institute conducts state-of-the-art research, patient care, and outreach/education.
Rutgers Cancer Institute of New Jersey attracts investigators from a wide range of scientific disciplines to focus on cancer research.
Based on research strengths and direction, members are organized into five programs comprised of faculty who form cohesive, interdisciplinary groups supported by peer-reviewed grants and Rutgers Cancer Institute of New Jersey shared resources. Programs are organized into three divisions: Basic Science Research, Clinical Research, and Population Research.
- Genomic Instability and Cancer Genetics (GICG)
Program Leaders: Zhiyuan Shen, MD, PhD and Chang S. Chan, PhD
- Cancer Pharmacology (CP)
Program Leaders: X. F. Steven Zheng, PhD and Stephen K. Burley, MD, DPhil
- Clinical Investigations and Precision Therapeutics (CIPT)
Program Leaders: Shridar Ganesan, MD, PhD and Janice M. Mehnert, MD
- Cancer Prevention and Control (CPC)
Program Leaders: Carolyn J. Heckman, PhD and Elisa V. Bandera, MD, PhD
Rutgers Cancer Institute of New Jersey has a unique niche among NCI-designated centers, as it benefits from opportunities as a matrix cancer center and at the same time has statewide authority beyond the university matrix, thus establishing an environment to foster and formalize a vision of transdisciplinary and translational research.